Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Secukinumab inflammatory bowel disease?How does Piqray treat PIK3CA-mutated cancer?Shingrix patent expiry?How effective is Ebglyss for moderate-to-severe atopic dermatitis?Were lipitor's side effects noticeable while swimming?
See the DrugPatentWatch profile for Calquence
Patient Experiences and Discussion with Calquence Calquence, also known as Acalabrutinib, is a medication used to treat certain types of blood cancers, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Here, we delve into patient experiences and discussions about Calquence. Side Effects and Patient Concerns Patients taking Calquence have reported various side effects, including fatigue, headache, and diarrhea [1]. Some patients have also experienced bleeding and bruising due to low platelet counts. It's essential for patients to monitor their blood counts regularly while on Calquence. How Does Calquence Compare to Other Treatments? Calquence has been compared to Bruton's tyrosine kinase (BTK) inhibitors, such as ibrutinib (Imbruvica). While both treatments have shown efficacy in treating MCL and CLL, Calquence has been associated with improved outcomes in some patients [2]. However, the choice between Calquence and other treatments ultimately depends on individual patient circumstances. Calquence vs. Keytruda Keytruda (pembrolizumab) is an immunotherapy medication used to treat various cancers, including MCL and CLL. While Calquence and Keytruda are distinct treatments, some studies have explored their combination in treating certain cancers [3]. Researchers are still investigating the potential benefits and risks of using Calquence with Keytruda. Biosimilars and Exclusivity The patent for Calquence is set to expire in 2028, potentially allowing biosimilars to enter the market [4]. Biosimilars can offer cheaper alternatives to name-brand medications, but their approval process and regulatory requirements differ from those for new treatments. Sources: [1] ClinicalTrials.gov. (n.d.). Acalabrutinib in Treating Patients With Chronic Lymphocytic Leukemia. [2] Calquence. (n.d.). Clinical trials. [3] Cancer Research UK. (n.d.). Immunotherapy and cancer. [4] DrugPatentWatch.com. (n.d.). Calquence Patent. Note: Always consult a healthcare professional before making any treatment decisions.
Other Questions About Calquence :